Risk of cardiovascular disease in elderly subjects with obesity and liver fibrosis and the potential benefit of statin treatment
Theel WB, de Jong VD, Castro Cabezas M, Grobbee DE, Jukema JW and Trompet S
Liver fibrosis progression is influenced by older age and cardiometabolic risk factors such as obesity and is associated with an increased risk of cardiovascular events. While statins may protect against cardiovascular complications, their effects in elderly individuals with obesity and liver fibrosis are unclear.
Gender Differences in a Real-World Registry Examining Coronary Lithotripsy for Calcified Lesions
van Oort MJH, Oliveri F, Ibtihal AA, Bingen BO, Claessen BEPM, Dimitriu-Leen AC, Vossenberg TN, Kefer J, Girgis H, van der Kley F, Jukema JW and Montero-Cabezas JM
Intravascular lithotripsy (IVL) has been established as a safe and effective treatment for coronary artery calcification (CAC). This study aimed to evaluate gender-related differences in the treatment with IVL in a real-world, all-comers international registry. Patients who underwent IVL between May 2019 and February 2024 were enrolled from the BENELUX-IVL registry. Patients were divided into men and women groups. Efficacy end points included device success (delivery of the IVL balloon across the target lesion and administration of therapy without related complications), technical success (thrombolysis in myocardial infarction 3 flow and residual stenosis <30% by quantitative coronary analysis and/or fluoroscopically) and procedural success (composite of technical success with absence of in-hospital major adverse cardiovascular events (MACE: cardiac death, myocardial infarction or target vessel revascularization). Safety end points were IVL-related complications and MACE at 1-year follow-up. 454 patients (73 ± 9.0 years) were treated with IVL, comprising 342 men (75%) and 112 women (25%). More women presented with acute coronary syndrome (41% in men vs 54% in women; p = 0.014) and aorto-ostial lesions (17% in men vs 29% in women; p = 0.009), whereas the SYNTAX score (23.5 ± 14.2 in men vs 17.1 ± 1.0 in women; p <0.001) was higher in men. Rates of device success (97% vs 98%; p = 1.000), technical success (90% vs 91%; p = 0.821) procedural success (90% vs 88%; p = 0.749), IVL-related complications (1% vs 2%; p = 0.362) and 1-year MACE rates (12% vs 17%; p = 0.456) were comparable. In conclusion, despite differences in clinical presentation and lesion types, IVL seems to be safe and effective for both genders across various clinical and anatomical scenarios.
Unilateral-access vs. bilateral-access in transfemoral transcatheter aortic valve replacement: A slim fit approach
Pereira AR, Al Jaff AAM, Montero Cabezas J, de Weger A, Candura D, Jukema JW, Arslan F, Regeer MV, Ajmone Marsan N and van der Kley F
Vascular complications remain prevalent on transfemoral transcatheter aortic valve replacement (TF-TAVR) with a significant proportion related to the secondary arterial access. We hypothesized that placing the second sheath ipsilateral and distal to the delivery sheath could reduce vascular complications with similar safety and efficacy.
Intravascular Lithotripsy in Acute Coronary Syndromes: Procedural and One-Year Clinical Outcomes From the BENELUX-IVL Registry
Oliveri F, van Oort MJH, Al Amri I, Bingen BO, Claessen BE, Dimitriu-Leen AC, Kefer J, Girgis H, Vossenberg T, van der Van der Kley F, Jukema JW and Montero-Cabezas JM
Despite the excellent success and safety of intravascular lithotripsy (IVL) in heavily calcified lesions, evidence in acute coronary syndromes (ACS) remains limited.
Evolving use and clinical outcomes of coronary intravascular lithotripsy: insights from an international, multicentre registry
van Oort MJH, Al Amri I, Bingen BO, Oliveri F, Claessen BEPM, Dimitriu-Leen AC, Vossenberg TN, Kefer J, Girgis H, van der Kley F, Jukema JW and Montero-Cabezas JM
Intravascular lithotripsy (IVL) is increasingly used for treatment of coronary artery calcification. This study aimed to evaluate contemporary utilisation patterns, safety and efficacy of IVL in an unselected real-world patient cohort.